Asset profile
Burixafor (TG-0054)
Small molecule
Evidence outlook · no controlled comparison
NCT01458288 · Multiple Myeloma, Non-hodgkin's Lymphoma, Hodgkin's Disease
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT01458288: This was a single-group, open-label study of 12 participants, with nonrandomized treatment cohorts receiving TG-0054 alone or with G-CSF and no placebo or active comparator. The primary outcome was a CD34+ stem-cell mobilization target, a surrogate measure, and although the target was reported in all participants, the study was not designed to establish a statistically tested treatment comparison.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 3 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 52 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Burixafor (TG-0054): this drug | Phase 2 | Small molecule | CXCR4 | ||
| Motixafortide | Approved | Peptide | CXCR4 | ||
| Plerixafor | Approved | Small molecule | CXCR4 | ||
| GPC-100 | Phase 2 | Small molecule | CXCR4 | ||
| AD-214 | Phase 1 | Antibody-derived scaffold | CXCR4 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.